Characterization model of the post COVID-19 condition based on immunological, biochemical, and cytokine markers
Bárbara Oliván-Blázquez; Marta Bona-Otal; Fátima Méndez-López; David Lerma-Irureta; Paula García-Izuel; Jesús Ibáñez-Ruiz; Alberto Montolío; María Ruiz-Herreros; Javier Godino; Beatriz Jimeno-Beltran; María del Mar Encabo-Berzosa; Izaskun Arenaz; Ana Medel-Martínez; Verónica Casado-Vicente; Mayte Coiras; Carlos Tellería-Orriols; Jon Schoorlemmer; Rosa Magallón-Botaya
Post-coronavirus disease condition (PCC) continues to affect many people globally, yet there remains a lack of diagnostic biomarkers to distinguish PCC from those recovered from acute COVID-19.
This study compared biomarkers between two age-and gender-matched groups: PCC individuals and those recovered within three months of acute COVID-19 in 2020 (n = 85 each). Biomarkers were assessed 12–24 months after initial diagnosis, examining biochemical profiles, blood cell counts, coagulation status, antibody serology, lymphocyte populations, and cytokine levels.
PCC individuals exhibited significant alterations in 49 of 167 markers, including K+ levels, αGAD antibodies, antithrombin III, insulin-like growth factor-binding protein 3 (IGFBP3), and interleukin-10 (IL-10).
A panel of αGAD, IL-10, potassium levels, and CD16brightCD56− cell presence distinguished PCC individuals from recovered patients with >88% accuracy and <92% precision.
Link | PDF (iScience) [Open Access]
Bárbara Oliván-Blázquez; Marta Bona-Otal; Fátima Méndez-López; David Lerma-Irureta; Paula García-Izuel; Jesús Ibáñez-Ruiz; Alberto Montolío; María Ruiz-Herreros; Javier Godino; Beatriz Jimeno-Beltran; María del Mar Encabo-Berzosa; Izaskun Arenaz; Ana Medel-Martínez; Verónica Casado-Vicente; Mayte Coiras; Carlos Tellería-Orriols; Jon Schoorlemmer; Rosa Magallón-Botaya
Post-coronavirus disease condition (PCC) continues to affect many people globally, yet there remains a lack of diagnostic biomarkers to distinguish PCC from those recovered from acute COVID-19.
This study compared biomarkers between two age-and gender-matched groups: PCC individuals and those recovered within three months of acute COVID-19 in 2020 (n = 85 each). Biomarkers were assessed 12–24 months after initial diagnosis, examining biochemical profiles, blood cell counts, coagulation status, antibody serology, lymphocyte populations, and cytokine levels.
PCC individuals exhibited significant alterations in 49 of 167 markers, including K+ levels, αGAD antibodies, antithrombin III, insulin-like growth factor-binding protein 3 (IGFBP3), and interleukin-10 (IL-10).
A panel of αGAD, IL-10, potassium levels, and CD16brightCD56− cell presence distinguished PCC individuals from recovered patients with >88% accuracy and <92% precision.
Link | PDF (iScience) [Open Access]
